GeoVax Labs (NASDAQ:GOVX) Posts Quarterly Earnings Results, Beats Estimates By $0.38 EPS

GeoVax Labs (NASDAQ:GOVX) posted its earnings results on Tuesday. The company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.38, Zacks reports. The firm had revenue of $2.79 million during the quarter, compared to analyst estimates of $1.84 million. During the same quarter in the prior year, the firm earned ($4.80) earnings per share.

GeoVax Labs Price Performance

Shares of GeoVax Labs stock traded down $0.52 during mid-day trading on Wednesday, reaching $2.73. 2,556,893 shares of the stock traded hands, compared to its average volume of 2,525,160. The business has a 50-day moving average of $2.44 and a 200 day moving average of $2.59. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $11.18.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on GOVX shares. Noble Financial lifted their price objective on shares of GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a report on Monday, August 19th. EF Hutton Acquisition Co. I raised GeoVax Labs to a “strong-buy” rating in a report on Tuesday, July 23rd. Alliance Global Partners assumed coverage on GeoVax Labs in a research report on Monday. They set a “buy” rating and a $15.00 price target on the stock. Roth Mkm started coverage on GeoVax Labs in a research report on Tuesday, July 16th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research note on Monday, August 12th. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, GeoVax Labs presently has a consensus rating of “Buy” and an average price target of $13.25.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.